BOSTON--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) presented new data in an osteosarcoma model demonstrating that mice treated with talabostat had a four- fold decrease in the number of primary tumors compared to saline treatment. In a separate experiment in the study, mice treated with talabostat had a 20-fold decrease in the number of gross metastatic lung nodules compared to saline treatment. The studies, conducted in the laboratory of Dr. Lee J. Helman, in the Pediatric Oncology Branch of the National Institutes of Health, were presented at the 21st Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTC) Development in Los Angeles, CA this past Saturday.
